Skip to main content
Premium Trial:

Request an Annual Quote

ArQule Will Use System Built With SignalGene for Its Own p38 Goals

NEW YORK, Feb. 21 - ArQule will apply the computational compound design system it co-designed with SignalGene to its own p38 MAP kinase drug-discovery program, the two companies said on Thursday.

 

The firms agreed in January 2001 to develop this system, and as part of that agreement will now apply it to design, generate, and evaluate new compounds that target p38 MAP kinase.

 

ArQule will produce the new compounds and test them for biological activity. The company has development rights to these compounds.

 

SignalGene, in return, will receive research fees and milestone payments for any relevant new compounds.

 

The system that the two companies developed employs interaction data and 3-D structure knowledge in order to come up with new drugs.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.